This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
-
Altimmune Clinical Study Site, Peoria, Arizona, United States, 85381
Altimmune Clinical Study Site, Tucson, Arizona, United States, 85712
Altimmune Clinical Study Site, North Little Rock, Arkansas, United States, 72117
Altimmune Clinical Study Site, Fresno, California, United States, 93720
Altimmune Clinical Study Site, La Jolla, California, United States, 92037
Altimmune Clinical Study Site, Pasadena, California, United States, 91105
Altimmune Clinical Study Site, Englewood, Colorado, United States, 80113
Altimmune Clinical Study Site, Bradenton, Florida, United States, 34201
Altimmune Clinical Study Site, Doral, Florida, United States, 33122
Altimmune Clinical Study Site, Doral, Florida, United States, 33122
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
Altimmune, Inc.,
2027-08-31